Home » Stocks » AUPH

Aurinia Pharmaceuticals Inc. (AUPH)

Stock Price: $15.16 USD -0.04 (-0.26%)
Updated December 1, 9:42 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 3.83B
Revenue (ttm) 117,000
Net Income (ttm) -156.60M
Shares Out 126.45M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE 1,428.57
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $15.16
Previous Close $15.20
Change ($) -0.04
Change (%) -0.26%
Day's Open 14.64
Day's Range 15.02 - 15.18
Day's Volume 1,318,706
52-Week Range 7.98 - 21.46

More Stats

Market Cap 3.83B
Enterprise Value 3.45B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 126.45M
Float n/a
EPS (basic) -1.50
EPS (diluted) -1.41
FCF / Share -0.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.12M
Short Ratio 4.45
Short % of Float n/a
Beta 0.87
PE Ratio n/a
Forward PE 1,428.57
P/FCF Ratio n/a
PS Ratio 32,768.80
PB Ratio 4.44
Revenue 117,000
Operating Income -120.21M
Net Income -156.60M
Free Cash Flow -102.54M
Net Cash 383.74M
Net Cash / Share 1.52
Gross Margin -44,912.82%
Operating Margin -102,746.15%
Profit Margin -133,849.60%
FCF Margin -87,641.03%
ROA -22.38%
ROE -59.93%
ROIC -254.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(51.91% upside)
Current: $15.16
Target: 23.03
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-31.32%10.77%141.62%-26.38%-15.47%-71.31%-84.18%-
Gross Profit0.320.460.420.
Operating Income-85.24-56.33-46.87-25.03-23.71-16.65-6.57-9.69
Net Income-124-64.12-70.79-23.30-18.61-19.42-2.66-9.69
Shares Outstanding85.5084.0552.8132.2931.8231.3731.37-
Earnings Per Share-1.33-0.76-0.92-0.66-0.58-0.67-0.42-2.73
Operating Cash Flow-63.46-51.61-41.17-18.71-17.77-16.91-4.62-6.51
Capital Expenditures-0.10-0.08-0.03-0.01-0.05-0.09-0.04-
Free Cash Flow-63.56-51.69-41.19-18.72-17.82-16.99-4.66-6.51
Cash & Equivalents30612617339.6515.7532.701.820.19
Total Debt------1.321.71
Net Cash / Debt30612617339.6515.7532.700.50-1.52
Book Value27411316635.9519.9633.8713.31-2.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aurinia Pharmaceuticals Inc.
Country Canada
Employees 62
CEO Peter S. Greenleaf

Stock Information

Ticker Symbol AUPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AUPH
IPO Date January 26, 1999


Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.